Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up/down: BANC +4% after earnings, DHT +14% and XXIA +6% after M&A news, DKS +2% after upgrade; TPX -24% after terminating contracts with Mattress Firm, BCS -2% after dg<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>IPGP</strong> +4.2%, <strong>BANC</strong> +3.7%, <strong>ARLP</strong> +2.7%, <strong>TRNC</strong> +1.7%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>DHT</strong> +14.3% (receives non-binding proposal to be acquired by Frontline (FRO) for $5.09 per share)</li><li><strong>XXIA</strong> +5.8% (confirms it will be acquired by Keysight Technologies (KEYS) for $19.65/share in cash)</li><li><strong>VOD</strong> +2.2% (confirms discussions with the Aditya Birla Group about an all share merger of Vodafone India)</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>CALA</strong> +28.3% (Calithera Biosciences & Incyte (INCY) announce global collaboration to develop & commercialize CB-1158)</li><li><strong>QURE</strong> +12.5% (announces FDA breakthrough therapy designation for AMT-060 in hemophilia B )</li><li><strong>FGEN</strong> +7.3% (announces Roxadustat meets primary endpoints in two phase 3 anemia studies of roxadustat in China)</li><li><strong>HMY</strong> +4.5% (provides H2 2016 guidance update)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>CLD</strong> +3.1% (upgraded to Overweight from Neutral at JP Morgan)</li><li><strong>CBL</strong> +1.9% (upgraded to Neutral from Sell at Citigroup)</li><li><strong>DKS</strong> +1.7% (upgraded to Buy from Neutral at Goldman)</li><li><strong>NTAP</strong> +1.3% (upgraded to Buy from Neutral at Goldman)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>SNE</strong> -3.3% (announces its Pictures unit to record impairment charge against the goodwill of JPY112.1 bln)</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>NRZ</strong> -1.4% (to acquire approximately $97 bln unpaid principal balance of mortgage servicing rights, increases dividend, offers prelim Q4 results)</li></ul><p><strong>Select financial related names showing weakness</strong>: <strong>SAN</strong> -2%, <strong>RBS</strong> -1.4%, <strong>DB</strong> -2.9%, .<br/> <br/> <strong>Select metals/mining stocks trading lower</strong>: <strong>MT</strong> -2.1%, <strong>AKS</strong> -2.1%, <strong>RIO</strong> -2%, <strong>BBL</strong> -1.8%, <strong>BHP</strong> -1.6%, <strong>VALE</strong> -1.6%, <strong>X</strong> -1.4%, .<br/> <br/> <strong>Select oil/gas related names showing early weakness</strong>: <strong>SSL</strong> -1.9%, <strong>RDS.A</strong> -1.8%, <strong>SDRL</strong> -1.7%, <strong>BP</strong> -1.7%, <strong>CHK</strong> -1%, .<br/> <br/> <strong>Other news</strong>:</p><ul><li><strong>OCRX</strong> -53.7% (announces top-line results for Phase 2b study in Hepatic Encephalopathy; primary and secondary endpoints showed trend and dose-related clinical benefit although not statistically significant )</li><li><strong>RGLS</strong> -28.9% (receives written communication from the FDA that the clinical development program for RG-101 remains on clinical hold )</li><li><strong>TPX</strong> -23.8% (after terminating contracts with largest customer Mattress Firm)</li><li><strong>PULM</strong> -23.4% (announces $5 mln registered direct offering at $2.50/share)</li><li><strong>FIT</strong> -9.8% (report that company plans to 5-10% of workforce amid weaker than expected Q4 earnings)</li><li><strong>IHG</strong> -2% (travel name weak in response to Trump exec orders over weekend)</li><li><strong>DAL</strong> -1.9% (after IT system failure on Sunday; reports all systems return to normal)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>ARRY</strong> -3% (downgraded to Mkt Perform from Outperform at Leerink Partners)</li><li><strong>HIMX</strong> -2.8% (downgraded to Neutral from Outperform at Robert W. Baird)</li><li><strong>BCS</strong> -2.6% (downgraded to Sell from Hold at Berenberg)</li><li><strong>DEO</strong> -2.1% (downgraded to Sell from Hold at Liberum)</li></ul></td> </tr></table>"